Results Snapshot
Figures in Cr
Standalone - Balance Sheet Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Balance Sheet Analysis Highlights
Borrowings
YoY Growth in year ended Mar 2025 is 60.00% vs 400.00% in Mar 2024
Other Long Term Liabilities
No Other Long Term Liabilities in the last few periods;
Fixed Assets
YoY Growth in year ended Mar 2025 is -100.00% vs 0.00% in Mar 2024
Investments
YoY Growth in year ended Mar 2025 is 3,401.64% vs 154.17% in Mar 2024
Current Assets
YoY Growth in year ended Mar 2025 is 5,720.00% vs -78.26% in Mar 2024
Compare Balance Sheet Results of Bacil Pharma
Figures in Cr
Standalone - Balance Sheet Results
Change(INR)
Change(%)
No of Months
12
12
EQUITY AND LIABILITIES
Share Capital
13.97
3.09
10.88
352.10%
Share Warrants & Outstandings
Total Reserve
11.46
68.71
-57.25
-83.32%
Shareholder's Funds
25.43
71.80
-46.37
-64.58%
Minority Interest
0.00
0.00
0.00
0.00%
Long-Term Borrowings
0.00
0.00
0.00
0.00%
Secured Loans
0.00
0.00
0.00
0.00%
Unsecured Loans
0.00
0.00
0.00
0.00%
Deferred Tax Assets / Liabilities
-0.05
0.11
-0.16
-145.45%
Other Long Term Liabilities
0.00
0.00
0.00
0.00%
Long Term Trade Payables
0.00
0.00
0.00
0.00%
Long Term Provisions
0.00
0.00
0.00
0.00%
Total Non-Current Liabilities
-0.05
0.11
-0.16
-145.45%
Current Liabilities
Trade Payables
0.00
38.70
-38.70
-100.00%
Other Current Liabilities
0.00
0.94
-0.94
-100.00%
Short Term Borrowings
0.16
9.91
-9.75
-98.39%
Short Term Provisions
0.00
0.02
-0.02
-100.00%
Total Current Liabilities
0.17
49.58
-49.41
-99.66%
Total Liabilities
25.55
121.49
-95.94
-78.97%
ASSETS
Non-Current Assets
0.00
0.00
0.00
0.00%
Gross Block
0.06
16.85
-16.79
-99.64%
Less: Accumulated Depreciation
0.06
6.37
-6.31
-99.06%
Less : Impairment of Assets
0.00
0.00
0.00
0.00%
Net Block
0.00
10.48
-10.48
-100.00%
Lease Adjustment
0.00
0.00
0.00
0.00%
Capital Work in Progress
0.00
0.00
0.00
0.00%
Intangible assets under development
0.00
0.00
0.00
0.00%
Pre-operative Expenses pending
0.00
0.00
0.00
0.00%
Assets in transit
0.00
0.00
0.00
0.00%
Non Current Investments
21.36
3.44
17.92
520.93%
Long Term Loans & Advances
1.28
0.75
0.53
70.67%
Other Non Current Assets
0.00
3.46
-3.46
-100.00%
Total Non-Current Assets
22.64
18.13
4.51
24.88%
Current Assets Loans & Advances
Current Investments
0.00
0.36
-0.36
-100.00%
Inventories
0.00
38.01
-38.01
-100.00%
Sundry Debtors
0.00
56.54
-56.54
-100.00%
Cash and Bank
2.86
0.16
2.70
1,687.50%
Other Current Assets
0.00
0.17
-0.17
-100.00%
Short Term Loans and Advances
0.05
8.13
-8.08
-99.38%
Total Current Assets
2.91
103.36
-100.45
-97.18%
Net Current Assets (Including Current Investments)
2.74
53.78
-51.04
-94.91%
Total Current Assets Excluding Current Investments
2.91
103.00
-100.09
-97.17%
Miscellaneous Expenses not written off
0.00
0.00
0.00
0.00%
Total Assets
25.55
121.49
-95.94
-78.97%
Contingent Liabilities
0.00
0.00
0.00
0.00%
Total Debt
0.16
9.91
-9.75
-98.39%
Book Value per share (adjusted)
18.20
232.39
-214.19
-92.17%
Annual - Borrowings
Borrowings 0.16 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 60.00% vs 400.00% in Mar 2024
Annual - Other Long Term Liabilities
No Other Long Term Liabilities in the last few periods
No Other Long Term Liabilities in the last few periods;
Annual - Fixed Assets
Fixed Assets 0.00 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -100.00% vs 0.00% in Mar 2024
Annual - Investments
Investments 21.36 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 3,401.64% vs 154.17% in Mar 2024
Annual - Current Assets
Current Assets 2.91 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 5,720.00% vs -78.26% in Mar 2024






